Print

RBC Life Sciences, Inc. Reports Sales and Earnings Growth in 2010  
3/8/2011 7:18:42 AM

IRVING, Texas, March 8, 2011 /PRNewswire/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported a 13% increase in consolidated net sales to $28.2 million for the year ended December 31, 2010, compared to net sales of $24.9 million for the same period during 2009. For 2010, the Company reported net earnings of $558,000, or $0.02 per diluted share, compared to a net loss of $335,000, or $0.02 per diluted share, during 2009.

"We significantly improved our financial performance in 2010 reporting sales growth in both our Nutritional Products segment and Medical Products segment," said RBC Life Sciences President and CEO, Clinton H. Howard. "We were particularly pleased to report sales growth of 22% to our international licensees, which is our largest revenue channel. This growth in sales along with expense reductions affected during 2010 resulted in an $893,000 improvement in net operating results and a return to profitability in 2010."

During 2010, net sales of Nutritional Products increased 15% to $21.6 million while net sales of Medical Products increased 6% to $6.5 million.

About RBC Life Sciences

Through wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

RBC Life Sciences, Inc.

Summary Results of Operations

(in thousands, except per share data)

(unaudited)



Years Ended December 31,


2010


2009

Net sales

$

28,157



$

24,925


Gross profit

13,686



12,802


Operating profit (loss)

1,044



(160)


Earnings (loss) before income taxes

891



(324)


Provision for income taxes

333



11


Net earnings (loss)

558



(335)






Earnings (loss) per share - basic

$

0.03



$

(0.02)


Earnings (loss) per share - diluted

0.02



(0.02)






Weighted average shares outstanding - basic

21,999



21,921


Weighted average shares outstanding - diluted

22,436



21,921





RBC Life Sciences, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)



December 31,


2010


2009

Assets




Cash and cash equivalents

$

4,220



$

3,972


Inventories

5,343



5,344


Other current assets

1,696



1,914


Total current assets

11,259



11,230


Other assets

7,085



7,383


Total assets

$

18,344



$

18,613






Liabilities and shareholders' equity




Accounts payable and accrued liabilities

$

3,087



$

2,729


Deferred revenue

2,490



3,669


Other current liabilities

168



156


Total current liabilities

5,745



6,554


Other liabilities

2,723



2,840


Shareholders' equity

9,876



9,219


Total liabilities and shareholders' equity

$

18,344



$

18,613





SOURCE RBC Life Sciences, Inc.


//-->